查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1631129

胃食道逆流症治療市場規模、佔有率、趨勢分析報告：按藥物類型、地區和細分市場預測，2025-2030 年

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

胃食道逆流症治療市場的成長與趨勢

根據 Grand View Research, Inc. 的一份新報告，全球胃食道逆流症 (GERD) 治療市場規模預計到 2030 年將達到 57.7 億美元。

預計 2025 年至 2030 年間市場複合年成長率為 2.0%。這種成長是由於胃食道逆流症和其他胃腸道疾病的盛行率不斷增加。此外，生活方式和飲食習慣的改變、GERD 管理設備的成功率低以及自我治療需求的增加進一步推動了該行業的發展。

胃食道逆流和其他胃病的盛行率不斷上升，推動著市場的成長。例如，據估計，總人口中約有13.98%患有GERD，這意味著全球整體約有10.3億人患有GERD。發病率的增加推動了對適當治療的需求。使用非處方藥治療不明疾病的人可能面臨更高的風險。未經治療的 GERD 不僅會增加不適感，還會導致進一步的醫療問題。

GERD 的治療通常包括改變生活方式、手術治療和藥物治療。對生活方式的改變沒有反應的患者可以接受治療性介入。治療方法包括抗酸藥、抗分泌藥物（如 PPI 和組織胺 (H2) 受體拮抗劑 (H2RA)）以及促動力藥物。法莫替丁和西咪替丁是經美國食品藥物管理局（FDA）批准的兩種 H2RA 藥物，目前可在美國櫃檯購買。另一種常用的 H2RA 藥物雷尼替丁因在活性成分中發現意外雜質而存在潛在的健康風險和安全問題，已被撤回。

此外，主要企業正致力於胃食道逆流症的治療。例如，2022 年 5 月，Phathom Pharmaceuticals 宣布 FDA核准Vonoprazan。 Vonoprazan 是一種用於治療成人各級糜爛性食道炎的藥物，旨在治癒和緩解胃灼熱。此外，2022 年 11 月，JB Pharma 推出了 Runraft，這是一種可快速緩解胃酸倒流和胃灼熱的新型配方。

胃食道逆流症治療市場報告重點

  • 制酸劑藥物將在 2024 年主導胃食道逆流治療市場，因為制酸劑可以抵消胃中的酸，從而快速、短期緩解症狀。
  • 由於不必要的情況而未經治療，從而引發進一步的醫療問題，這推動了對適當治療的需求。
  • 新興市場的關鍵參與企業正致力於開發可幫助緩解胃食道逆流症 (GERD) 所引起的不適的藥物。
  • 北美佔據了最大的市場佔有率，這得益於診斷技術的不斷進步，促進了殘疾患者的康復。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. GERD 治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

4. GERD 治療市場：按藥物類型分類的業務分析

  • 2024 年和 2030 年各藥物類型的市場佔有率
  • 藥物類型細分儀表板
  • 2018 年至 2030 年按藥物類型分類的市場規模、預測與趨勢分析
  • 制酸劑
  • H2受體阻斷劑
  • 質子幫浦抑制劑 (PPI)
  • 促動力劑

第 5 章 胃食道逆流症治療市場：按地區分類的估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區，2018 年至 2030 年
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區，2018 年至 2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AstraZeneca
    • Eisai Co., Ltd.
    • GSK plc.
    • Takeda Pharmaceutical Company Limited
    • Ironwood
    • Johnson & Johnson Services, Inc.
    • SFJ Pharmaceuticals
    • Sebela Pharmaceuticals
    • Phathom Pharmaceuticals, Inc.
    • Camber Pharmaceuticals, Inc.
Product Code: GVR-1-68038-778-0

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends:

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights:

  • Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
  • Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
  • Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
  • North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Antacids
    • 4.4.1. Antacids Market, 2018 - 2030 (USD Million)
  • 4.5. H2 Receptor Blockers
    • 4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
  • 4.6. Proton Pump Inhibitors (PPIs)
    • 4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
  • 4.7. Pro-kinetic Agents
    • 4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework
      • 5.4.2.3. Competitive Insights
      • 5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework
      • 5.4.3.3. Competitive Insights
      • 5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework
      • 5.4.4.3. Competitive Insights
      • 5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework
      • 5.5.2.3. Competitive Insights
      • 5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework
      • 5.5.3.3. Competitive Insights
      • 5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework
      • 5.5.4.3. Competitive Insights
      • 5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Regulatory Framework
      • 5.5.5.3. Competitive Insights
      • 5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Regulatory Framework
      • 5.5.6.3. Competitive Insights
      • 5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.7. Norway
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Regulatory Framework
      • 5.5.7.3. Competitive Insights
      • 5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.8. Denmark
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Regulatory Framework
      • 5.5.8.3. Competitive Insights
      • 5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.9. Sweden
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Regulatory Framework
      • 5.5.9.3. Competitive Insights
      • 5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework
      • 5.6.2.3. Competitive Insights
      • 5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework
      • 5.6.3.3. Competitive Insights
      • 5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework
      • 5.6.4.3. Competitive Insights
      • 5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. South Korea
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework
      • 5.6.5.3. Competitive Insights
      • 5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.6. Australia
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Regulatory Framework
      • 5.6.6.3. Competitive Insights
      • 5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Regulatory Framework
      • 5.6.7.3. Competitive Insights
      • 5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Regulatory Framework
      • 5.7.2.3. Competitive Insights
      • 5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Regulatory Framework
      • 5.7.3.3. Competitive Insights
      • 5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Regulatory Framework
      • 5.8.2.3. Competitive Insights
      • 5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Regulatory Framework
      • 5.8.3.3. Competitive Insights
      • 5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Regulatory Framework
      • 5.8.4.3. Competitive Insights
      • 5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Regulatory Framework
      • 5.8.5.3. Competitive Insights
      • 5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. AstraZeneca
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Eisai Co., Ltd.
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. GSK plc.
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Takeda Pharmaceutical Company Limited
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Ironwood
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. Johnson & Johnson Services, Inc.
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Product Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. SFJ Pharmaceuticals
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Product Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Sebela Pharmaceuticals
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Product Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Phathom Pharmaceuticals, Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Product Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Camber Pharmaceuticals, Inc.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Product Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global gastroesophageal reflux disease therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 5 North America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 Mexico gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 12 UK gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 France gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 Italy gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 16 Spain gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Norway gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 18 Denmark gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Sweden gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Japan gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 China gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 24 India gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Australia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 South Korea gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Thailand gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 28 Latin America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 29 Latin America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Brazil gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 31 Argentina gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 South Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 UAE gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gastroesophageal reflux disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Gastroesophageal reflux disease therapeutics market dynamics
  • Fig. 12 Gastroesophageal reflux disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Gastroesophageal reflux disease therapeutics market: PESTLE analysis
  • Fig. 14 Gastroesophageal reflux disease therapeutics market: Drug type segment dashboard
  • Fig. 15 Gastroesophageal reflux disease therapeutics market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Antacids market, 2018 - 2030 (USD Million)
  • Fig. 17 H2 receptor blockers market, 2018 - 2030 (USD Million)
  • Fig. 18 Proton pump inhibitors (PPIs) market, 2018 - 2030 (USD Million)
  • Fig. 19 Pro-kinetic agents market, 2018 - 2030 (USD Million)
  • Fig. 20 Gastroesophageal reflux disease therapeutics market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 Europe gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework